Moreover, the substantial efficacy of cell-based immunotherapies that engage T cells to BCMA-expressing myeloma cells and redirect subsequent lysis of myeloma cells have recently been uncovered by the emergence of BCMA-directed CAR-T cell and BsAb constructs (8, 13, 14). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.